摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-ethyladamantan-1-yl)methanol | 1291486-01-5

中文名称
——
中文别名
——
英文名称
(3-ethyladamantan-1-yl)methanol
英文别名
(3-Ethyl-1-adamantyl)methanol
(3-ethyladamantan-1-yl)methanol化学式
CAS
1291486-01-5
化学式
C13H22O
mdl
——
分子量
194.317
InChiKey
VNWYCXNTFCFKAT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    275.7±8.0 °C(Predicted)
  • 密度:
    1.049±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 危险等级:
    IRRITANT

反应信息

  • 作为反应物:
    描述:
    (3-ethyladamantan-1-yl)methanol硝酸一水合肼 作用下, 以 正丁醇 为溶剂, 反应 4.0h, 生成 (3-ethyl-3-hydroxyadamantan-1-yl)methanol
    参考文献:
    名称:
    (3-羟基金刚烷-1-基)甲醇的合成
    摘要:
    已经开发了一种便利的方法,用于以烟酰胺硝化酸将金刚烷-1-基甲醇硝化并随后用水合肼还原中间体硝酸酯来合成(3-羟基金刚烷-1-基)-甲醇。通过还原1-硝基-3-(硝基甲基)金刚烷也获得了标题二醇。硝基氧化过程伴随着氧化,形成取代的金刚烷-1-羧酸。
    DOI:
    10.1134/s107042801809004x
点击查看最新优质反应信息

文献信息

  • Synthesis of di(adamantylalkyl) tosyloxymethylphosphonates and di(adamantyloxyalkyl) tosyloxymethylphosphonates
    作者:A. N. Reznikov、M. Yu. Skomorokhov、Yu. N. Klimochkin
    DOI:10.1134/s1070363212050052
    日期:2012.5
    A simple method for the synthesis of esters of tosyloxymethylphosphonic acid based on the adamantane series of alcohols and diethyl tosyloxymethyl phosphonate was developed. The di(adamantylalkyl) and di(adamantyloxyalkyl) tosyloxymethylphosphonates are of interest as key compounds in the synthesis of antiviral drugs of the nucleoside phosphonate class.
  • Method for Inhibition of Potential-Dependent Cation Channel
    申请人:Takatoku Hiroko
    公开号:US20130045177A1
    公开(公告)日:2013-02-21
    An excellent potential-dependent cation channel inhibitor or an excellent masking agent is provided. Disclosed is a method for inhibiting a potential-dependent cation channel or a method for masking olfaction, both of which include administering an adamantane derivate represented by the following formula (1) or a salt thereof [wherein R′ and R 2 are identical with or different from each other, and each represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms; and X represents —OH, —R 3 —OH (wherein R 3 represents an alkylene group having 1 to 6 carbon atoms), —NH 2 , —R 4 —NH 2 (wherein R 4 represents an alkylene group having 1 to 6 carbon atoms), —COOH, —R 5 —COOH (wherein R 5 represents an alkylene group having 1 to 6 carbon atoms), —CO-R 6 (wherein R 6 represents an alkyl group having 1 to 6 carbon atoms), —CO—R 7 —COO—R 8 (wherein R 7 represents an alkylene group having 1 to 6 carbon atoms, and R 8 represents an alkyl group having 1 to 6 carbon atoms), or —NHCO—R 9 (wherein R 9 represents an alkyl group having 1 to 6 carbon atoms)].
  • US8481016B2
    申请人:——
    公开号:US8481016B2
    公开(公告)日:2013-07-09
查看更多